Clinical trials: Sentinel Nodes
Early Stage Breast Carcinoma
Sentinel Node Vs Observation After Axillary Ultra-souND
The hypothesis of this trial are that: avoiding axillary surgery does not worsen the outcome of patients with small breast cancer the absence of the pathological information on the risk of recurrence given by nodal status is not…
- Trial name
- SOUND (NCT02167490)
- Testing
- Arm 1: sentinel node biopsy
- Where
- 18 sites in Chile, Italy and 2 more
- Volunteers
- 1,560 people
- Sponsor
- European Institute of Oncology
Pediatric Solid Tumors, Rhabdomyosarcoma
Tumor-Lymph Node Mapping
The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node…
- Conditions
- Pediatric Solid Tumors, Rhabdomyosarcoma, Sarcoma, Germ Cell Tumor
- Trial name
- T-LyM (NCT07054944)
- Testing
- ICG (Indocyanine Green)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Melanoma
Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma
This study aims at assessing the role of MerlinTM and ctDNA in predicting the nodal status in patients with >pT3b melanoma, therefore candidate for adjuvant therapy regardless of sentinel lymph node status.
- Trial name
- CORRESPOND (NCT06566404)
- Volunteers
- 200 people
- Sponsor
- European Institute of Oncology
Stage II Melanoma
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a…
- Trial name
- Neo ReNi II (NCT05418972)
- Testing
- Relatlimab and nivolumab fixed dose combination (FDC)
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Melanoma Institute Australia
Melanoma, Stage I, Melanoma, Stage II
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG
In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.
- Conditions
- Melanoma, Stage I, Melanoma, Stage II, Melanoma Stage III
- Trial name
- MelanooMSOT (NCT05467137)
- Testing
- MSOT
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Epithelial Ovarian Cancer, Sentinel Lymph Node Detection
The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian Cancer
This study is a single-arm, open, multicenter, exploratory clinical study to evaluate the feasibility, sensitivity, and specificity of sentinel lymph node (SLN) mapping technology in the population with early epithelial ovarian…
- Trial name
- NCT06673511
- Testing
- Lymph node visualization, No visualization of lymph nodes
- Volunteers
- 246 people
- Sponsor
- Anhui Provincial Hospital
Endometrial Cancer, Lymph Node Metastasis
Staging Endometrial caNcer Based on molEcular ClAssification
The SENECA study tries to evaluate the rate of lymph node involvement depending on the molecular subgroup in early-stage endometrial cancer (I/II) patients undergoing surgery as part of their treatment.
- Conditions
- Endometrial Cancer, Lymph Node Metastasis, Sentinel Lymph Node
- Trial name
- NCT05707312
- Where
- Spain
- Volunteers
- 1,032 people, healthy volunteers welcome
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Squamous Cell Carcinoma of Head and Neck
Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC
The study involves head and neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, larynx or hypopharynx with positive nodes on only one side of the neck and no distant metastasis treated by primary…
- Trial name
- SEMIRAHN (NCT04688528)
- Testing
- Dose de-escalation and / or Volume de-escalation
- Where
- 10 sites in Belgium
- Volunteers
- 147 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer Female, Early-stage Breast Cancer
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011…
- Conditions
- Breast Cancer Female, Early-stage Breast Cancer, Lymph Node Metastases, Axillary Metastases
- Trial name
- TADEN (NCT04671511)
- Testing
- Targeted Axillary Dissection, Ultrasound of the axilla
- Where
- 3 sites in Canada
- Volunteers
- 98 people
- Sponsor
- Jewish General Hospital
Breast Neoplasm Female, Lymphatic Metastasis
Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial
The OBSERB study is a multi-center, non-blinded, pragmatic, parallel, randomized controlled trial in which patients with cT1-3N1 and ycN0 breast cancer.
- Trial name
- OBSERB (NCT04116125)
- Testing
- Radiotherapy
- Volunteers
- 1,380 people
- Sponsor
- Kyungpook National University Chilgok Hospital
Breast Cancer
Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes
Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and…
- Trial name
- VSNBNAC (NCT01622478)
- Testing
- Sentinel lymph node biopsy, Neoadjuvant chemotherapy, complete axillary lymph node dissection
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Gangnam Severance Hospital
Lymph Node Cancer Metastatic
Axillary Reverse Mapping in Breast Cancer
The axillary mapping reverse (ARM) consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema.
- Trial name
- ARM (NCT05040685)
- Testing
- Axillary mapping reverse
- Where
- Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari de Bellvitge
Breast Cancer
Current Value of Axillary Ultrasound in the Staging of Breast Cancer. Is BSGC Still Necessary?
AUS/FNAC allows the identification of tumors without axillary tumor involvement, or with low axillary tumor burden, many of which do not benefit from SLNB, in the staging of early breast cancer.
- Trial name
- NCT03193008
- Where
- Spain
- Volunteers
- 1,400 people
- Sponsor
- Corporacion Parc Tauli
Endometrial Cancer, Sentinel Lymph Node Detection
Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer
Patients with endometrial cancer who have planned robotic laparoscopic hysterectomy and full bilateral pelvic and para-aortic lymphadenectomy will receive injections of a fluorescent dye, Indocyanine green (ICG).
- Trial name
- NCT02131558
- Testing
- ICG Dye
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Lahey Clinic
Breast Cancer, Neoadjuvant Therapy
No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy
NEO-NAUTILUS is a prospective, multicenter, randomized phase III clinical trial to evaluate whether omitting axillary lymph node surgery (ALND or SLNB) in clinically lymph node-negative breast cancer patients after neoadjuvant…
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy
- Trial name
- Neo-NAUTILUS (NCT06704945)
- Testing
- No axillary surgery, Axillary surgery
- Where
- South Korea
- Volunteers
- 464 people
- Sponsor
- Seoul National University Hospital
Early Gastric Cancer
Sentinel Node Resection With or Without LECS After Noncurative ESD for EGC
For patients with non-curative resection after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), complementary surgery is generally recommended.
- Trial name
- Co-SNARE (NCT07295002)
- Testing
- ICG-guided lymphadenectomy, Laparoscopic and endoscopic cooperative surgery (LECS)
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Region Stockholm
Invasive Breast Cancer
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
Data from cohorts, prospective studies and one randomized trial (ASCOG Z0011) support the hypothesis that omission of additional axillary dissection in case of positive sentinel node has a limited impact on overall survival and…
- Trial name
- NCT01717131
- Testing
- Surgery for standard axillary node dissection, No axillary lymph node dissection
- Where
- France
- Volunteers
- 2,228 people
- Sponsor
- Institut Paoli-Calmettes
Early Gastric Cancer
Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2)
Laparoscopic sentinel lymph node dissection and stomach preserving surgery in early gastric cancer is less invasive method which can increase quality of life.
- Trial name
- NCT03837301
- Testing
- NESS-EFTR with sentinel lymph node navigation
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- National Cancer Center, Korea
Cancer of the Breast
Axillary Reverse Mapping
We hypothesize that variations in anatomic location of the arm lymphatic drainage system put the arm lymphatics at risk for disruption during a SLNB and / or ALND.
- Trial name
- ARM (NCT00572481)
- Testing
- Axillary Reverse Mapping
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Arkansas
Early Stage Breast Cancer
Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)
A downstaging of axillary tumor-spread can be achieved in about 40% of the patients receiving neoadjuvant chemotherapy (NACT). The impact of NACT on loco-regional tumor control has not yet been sufficiently investigated.
- Trial name
- NCT03102307
- Testing
- Not suitable for TAD, Suitable for TAD
- Where
- 3 sites in Germany
- Volunteers
- 548 people
- Sponsor
- Kliniken Essen-Mitte